ALK NSCLC treatment, ‘Zykadia’ will be applied for insurance benefit

As approved in the health insurance benefit, another ALK(Anaplastic Lymphoma Kinase) positive non-small cell lung cancer treatment can now be clinically used.

In the ‘Announced Amendment on Drugs Prescribed for Cancer Patients’ recently revealed by the Health Insurance Review & Assessment Service, the health insurance standard of the Novartis’ ALK targeted therapy, ‘Zykadia(generic name: cerit...